Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
Human Psychopharmacology
|
August 5, 2014
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Stuart A Montgomery, Rebecca Z Nielsen, Lis H Poulsen, et al.
International Clinical Psychopharmacology
|
November 1, 2013
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
Stuart A Montgomery, Lucilla Mansuy, Adam C Ruth, et al.
The Journal of Clinical Psychiatry
|
May 13, 2014
Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies
Richard Weisler, Stuart A Montgomery, Willie R Earley, et al.
Journal of Psychiatric Research
|
August 23, 2002
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
Stuart A Montgomery, David V Sheehan, Paolo Meoni, et al.
International Clinical Psychopharmacology
|
June 21, 2003
Improving the chance of recovery from the short- and long-term consequences of depression
Hans-Jürgen Möller, Koen Demyttenaere, Emilio Sacchetti, et al.
The Journal of Clinical Psychiatry
|
July 18, 2006
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
Stuart A Montgomery, Kathy Tobias, Gwen L Zornberg, et al.
International Clinical Psychopharmacology
|
October 27, 2011
Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies
Richard H Weisler, Stuart A Montgomery, Willie R Earley, et al.
The Journal of Clinical Psychiatry
|
November 2, 2005
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder
Stuart A Montgomery, Rico Nil, Natalie Dürr-Pal, et al.
The Journal of Clinical Psychiatry
|
April 21, 2004
Venlafaxine versus placebo in the preventive treatment of recurrent major depression
Stuart A Montgomery, Richard Entsuah, David Hackett, et al.
The Journal of Clinical Psychiatry
|
May 10, 2013
Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study
Stuart A Montgomery, Lucilla Mansuy, Adam Ruth, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
Human Psychopharmacology
|
August 5, 2014
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Stuart A Montgomery, Rebecca Z Nielsen, Lis H Poulsen, et al.
International Clinical Psychopharmacology
|
November 1, 2013
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
Stuart A Montgomery, Lucilla Mansuy, Adam C Ruth, et al.
The Journal of Clinical Psychiatry
|
May 13, 2014
Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies
Richard Weisler, Stuart A Montgomery, Willie R Earley, et al.
Journal of Psychiatric Research
|
August 23, 2002
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
Stuart A Montgomery, David V Sheehan, Paolo Meoni, et al.
International Clinical Psychopharmacology
|
June 21, 2003
Improving the chance of recovery from the short- and long-term consequences of depression
Hans-Jürgen Möller, Koen Demyttenaere, Emilio Sacchetti, et al.
The Journal of Clinical Psychiatry
|
July 18, 2006
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
Stuart A Montgomery, Kathy Tobias, Gwen L Zornberg, et al.
International Clinical Psychopharmacology
|
October 27, 2011
Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies
Richard H Weisler, Stuart A Montgomery, Willie R Earley, et al.
The Journal of Clinical Psychiatry
|
November 2, 2005
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder
Stuart A Montgomery, Rico Nil, Natalie Dürr-Pal, et al.
The Journal of Clinical Psychiatry
|
April 21, 2004
Venlafaxine versus placebo in the preventive treatment of recurrent major depression
Stuart A Montgomery, Richard Entsuah, David Hackett, et al.
The Journal of Clinical Psychiatry
|
May 10, 2013
Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study
Stuart A Montgomery, Lucilla Mansuy, Adam Ruth, et al.
Page
of 5